Premium
Inhibition of high glucose‐induced protein mono‐ADP‐ribosylation restores neuritogenesis and sodium‐pump activity in SY5Y neuroblastoma cells
Author(s) -
Di Giulio Anna Maria,
Lesma Elena,
Germani Elena,
Gorio Alfredo
Publication year - 1999
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/(sici)1097-4547(19990901)57:5<663::aid-jnr8>3.0.co;2-6
Subject(s) - endocrinology , sh sy5y , medicine , fructose , chemistry , neuroblastoma , retinoic acid , diabetes mellitus , neurite , galactose , in vitro , cell culture , biology , biochemistry , gene , genetics
The exposure of SY5Y neuroblastoma cells to high concentrations of glucose, fructose, or galactose is an experimental model commonly used for in vitro evaluation of typical neuronal alterations observed in diabetes mellitus. In the present study, we observed that 2 weeks of exposure to high carbohydrate concentrations caused both a significant impairment in neurite formation induced by supplementation of retinoic acid or by subtraction of fetal calf serum to the culture medium and a marked reduction in Na + –K + ‐ATPase activity. However, only the exposure to high millimoles of glucose caused an enhancement of mono‐ADP‐ribosylation, typical of diabetes mellitus, affecting at leat five proteins. The concomitant exposure to high glucose and to silybin, a mono‐ADP‐ribosylation inhibitor, normalized the extent of ADP‐ribosylation of the five proteins and counteracted the inhibitory effects of high glucose on Na + ‐pump activity and on neuritogenesis. Conversely, the supplementation of silybin did not prevent fructose and galactose inhibitory effects on Na + ‐pump activity and neurite formation. These data confirm those of previous reports suggesting a link between excessive protein mono‐ADP‐ribosylation and the onset of diabetic complications such as diabetic neuropathy. J. Neurosci. Res. 57:663–669, 1999. © 1999 Wiley‐Liss, Inc.